Drawing for MYCOMEDICA

USPTO serial 97204083

MYCOMEDICA

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
MARTIN, LIEF ANDREW
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with MYCOMEDICA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Emily T. Kappers

Emily T. Kappers CROWELL & MORING LLPP.O. BOX 10395CHICAGO, IL 60610UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Dermatological pharmaceutical products; Pharmaceutical skin lotions; Digestives for pharmaceutical purposes; Pharmaceutical preparations for skin care; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical agents affecting digestive organs; Pharmaceutical agents affecting sensory organs; Pharmaceutical preparations for peripheral nervous system; Pharmaceutical products for the treatment and prevention of psychiatric and neurological disease; Nutraceuticals for use as a dietary supplement; Nutraceuticals for the treatment and prevention of psychiatric and neurological disease; Dietary supplements; Dietary and nutritional supplements; Therapeutic pharmaceutical for the treatment of psychiatric and neurological disease; Therapeutic pharmaceutical for the treatment of mental health disorders; Extracts from plants for pharmaceutical purposes; Herbal extracts for pharmaceutical purposes; Mushroom extracts for pharmaceutical purposes; Fungal extracts for pharmaceutical purposes; Fungal extracts sold as a component ingredient of nutritional supplements and vitamins; Topical anesthetics; Topical analgesics; Topical analgesic creams; Topical gel for medical and therapeutic treatments, namely, for dermatological useACTIVE—
042Pharmaceutical research services; Pharmaceutical research and development; Pharmaceutical drug development services; Development of pharmaceutical preparations and medicinesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Feb 20, 2024MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Feb 19, 2024ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 24, 2023EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 22, 2023EX1GSOU EXTENSION 1 GRANTED—
Jun 22, 2023EXT1SOU EXTENSION 1 FILED—
Jun 22, 2023EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jan 17, 2023NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Nov 22, 2022NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Nov 22, 2022PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Nov 2, 2022NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Oct 14, 2022CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Oct 14, 2022XAECEXAMINER'S AMENDMENT ENTERED—
Oct 14, 2022GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Oct 14, 2022GNEAEXAMINERS AMENDMENT E-MAILED—
Oct 14, 2022CNEAEXAMINERS AMENDMENT -WRITTEN—
Oct 11, 2022DOCKASSIGNED TO EXAMINER—
Jan 10, 2022NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 8, 2022NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance